Search Results
Aug 14, 2025, 15:13 ET Emmaus Life Sciences Reports Quarterly Financial Results
DiseaseThere are approximately 100,000 people living with sickle cell disease (SCD) in the United States and millions more globally. The sickle gene is found in every ethnic group, not just among those of African descent; and in the United States an estimated 1-in-365 African Americans and 1-in-16,300
More news about: Emmaus Life Sciences, Inc.
Aug 14, 2025, 09:20 ET Made Scientific and New Jersey Delegates Celebrate Grand Opening of Flagship Cell Therapy Manufacturing Facility
region, underscoring New Jersey's role in the growing national landscape of advanced biomanufacturing and cell and gene therapy innovation.
More news about: Made Scientific, Inc.
Aug 14, 2025, 08:45 ET Investors in Sarepta Therapeutics, Inc. Should Contact The Gross Law Firm Before August 25, 2025 to Discuss Your Rights - SRPT
during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) ELEVIDYS, a prescription gene therapy for Duchenne, posed significant safety risks to patients; (ii) ELEVIDYS trial regimes and protocols failed to detect severe side effects; (iii)
More news about: The Gross Law Firm
Aug 14, 2025, 08:36 ET Nanoscope Therapeutics Announces Publication of STARLIGHT Phase 2 Study Evaluating MCO-010 Gene-Agnostic Therapy in Patients with Stargardt Disease
Nanoscope Therapeutics Inc., a biotechnology company committed to developing and commercializing novel gene-agnostic therapies for patients suffering vision loss from retinal degenerative diseases, today announced the publication of positive results from its
More news about: Nanoscope Therapeutics
Aug 14, 2025, 07:02 ET BrainStorm Cell Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update
with Minaris Advanced Therapies, a global contract development and manufacturing organization (CDMO) specializing in cell and gene therapies, to manufacture NurOwn for the upcoming Phase 3b clinical trial.NurOwn® data selected as Breakthrough
More news about: BrainStorm Cell Therapeutics Inc.
Aug 14, 2025, 07:00 ET ScaleReady Announces Award of a G-Rex® Grant to the Gates Institute's Translational Sciences Laboratory
supports researchers and clinicians who specialize in regenerative, cell and gene therapies, accelerating their discoveries from concepts to cures. About ScaleReadyScaleReady provides the field of cell and gene-modified cell therapy (CGT) with a G-Rex centric manufacturing platform
More news about: Bio-Techne Corporation
Aug 14, 2025, 07:00 ET BioLineRx Reports Second Quarter 2025 Financial Results and Provides Corporate Update
combination.Sickle Cell Disease (SCD) & Gene Therapy Ongoing Phase 1 clinical trial evaluating motixafortide as monotherapy and in combination with natalizumab for stem cell mobilization for gene therapies in sickle cell disease continues to progress. The
More news about: BioLineRx Ltd.
Aug 13, 2025, 16:05 ET Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update
Pipeline Updates ELVN-001 is a potent, highly selective, small molecule kinase inhibitor designed to specifically target the BCR::ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia (CML). In June 2025,
More news about: Enliven Therapeutics, Inc.
Aug 13, 2025, 11:12 ET 'Functional Unemployment' Rises; Black, Hispanic Workers Take Biggest Hit, Says Ludwig Institute
@LISEP_org. About Gene LudwigIn addition to his role as LISEP chair, Gene Ludwig is a managing partner of Canapi LLC, a financial technology venture fund. He is the founder
More news about: Ludwig Institute for Shared Economic Prosperity
Aug 13, 2025, 10:32 ET Whole Genome Sequencing Market to Reach New Heights by 2030
cancer, rare inherited disorders, and neurological diseases. Its ability to provide comprehensive genomic information helps reduce reliance on single-gene tests or invasive procedures. WGS is also increasingly used in drug development to identify better disease targets and select suitable patients for
More news about: BCC Research LLC
Aug 13, 2025, 09:18 ET Phosphorex Appoints Jerry Williamson as Chief Executive Officer
expand its capabilities in lipid nanoparticle (LNP) formulation, process development, and cGMP manufacturing to support the next generation of RNA, gene, and small molecule therapeutics. "I'm excited to join Phosphorex and lead a team that's at the forefront of enabling drug delivery innovation,"
More news about: Phosphorex LLC
Aug 13, 2025, 08:33 ET For the Third Time, Navion Makes the Inc. 5000 List of the Fastest-Growing Private Companies in America
high-stakes environment. As employers and health plans face mounting pressure from the financial impact of groundbreaking therapies like GLP-1s and gene therapies, Navion stands out for its ability to anticipate—not just react to—market shifts. Through custom strategies, proactive clinical oversight,
More news about: Navion
Aug 13, 2025, 08:00 ET Apertura Gene Therapy Licenses Blood-Brain Barrier-Penetrant AAV Capsid to Multiple Partners Advancing Central Nervous System Treatments
well-tolerated gene therapy capsid. NEW YORK, Aug. 13, 2025 /PRNewswire/ -- Apertura Gene Therapy, a biotechnology company focused on innovative gene therapy
More news about: Apertura Gene Therapy
Aug 13, 2025, 08:00 ET Seal Rock Therapeutics Joins The Michael J. Fox Foundation's LITE Program to Advance New Therapies Targeting LRRK2 for Parkinson's Disease
leaders, and provide preclinical and clinical resources to establish best practices for advancing LRRK2 targeted therapeutics. Mutations in the LRRK2 gene linked to Parkinson's disease were first discovered in 2004 and are now understood to be the most common cause of inherited PD. Built on MJFF's dedication
More news about: Seal Rock Therapeutics
Aug 12, 2025, 17:31 ET Tumor-Infiltrating Lymphocyte Therapy Market Gains Momentum with Expanding Oncology Applications | DelveInsight
CRISPR-engineered Tumor Infiltrating Lymphocyte (eTIL) therapy. KSQ-004EX consists of eTIL in which the SOCS1 and Regnase-1 genes are inactivated by CRISPR/Cas9 gene editing, giving it the potential to be a best-in-class treatment for a variety of solid tumor indications. KSQ's CRISPRomics platform identified SOCS1
More news about: DelveInsight Business Research, LLP
Aug 12, 2025, 15:26 ET Children's Hospital of Philadelphia, Clinic for Special Children Discover Ultra Rare Form of Neuroinflammatory Disease is Much More Common in Old Order Amish than General Population
at CHOP presenting with acute neuroinflammatory symptoms of unknown cause. Rapid exome sequencing identified a variant of unknown significance in the gene CFI, which was found to be the underlying cause of her disease and directed her targeted management and recovery. This case motivated researchers
More news about: Children's Hospital of Philadelphia
Aug 12, 2025, 14:04 ET Global Contract Manufacturing Market on Track for $968.7 Billion by 2030
delivers value-added engineering services. IndyGeneUS Bio: IndyGeneUS Bio is an innovative cell and gene therapy company focused on diversity-driven gene target discoveries and data security. In 2024, the company raised $1.8 million in a round
More news about: BCC Research LLC
Aug 12, 2025, 13:00 ET 80-20 - WITH RECORD OF PUNISHING SINOPHOBIA IN POLITICS - CONDEMNS SINOPHOBIC ATTACK ON GENE WU
Asian American political organization in the country, strongly condemns a Sinophobic attack against Texas State Representative Gene Wu by Texas Republicans. On August 6, 2025, the Texas Tribune reported
More news about: 80-20 Educational Foundation
Aug 12, 2025, 11:34 ET FDA Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease
therapies to treat chronic, debilitating lung diseases. The Company's early-stage programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Headquartered in Bridgewater,
More news about: Insmed Incorporated
Aug 12, 2025, 11:05 ET Pew Awards 22 Researchers Biomedical Science Grants
Yale School of MedicineDr. Reilly will design programmable, synthetic cis-regulatory elements—DNA sequences that control gene expression—to facilitate the delivery and activation of therapeutic cargos to specific target tissues. Berna Sozen,
More news about: The Pew Charitable Trusts
Aug 12, 2025, 11:00 ET Mice Model Market worth US$2.74 billion in 2030 with 10.0% CAGR | MarketsandMarkets™
application. CRISPR/Cas9 systems use short guide RNAs and the Cas9 endonuclease to induce targeted DNA cleavage, enabling gene knockouts, base editing, and transgenesis. This method allows direct gene editing at the single-cell embryo stage, bypassing traditional breeding cycles and reducing timelines for generating
More news about: MarketsandMarkets
Aug 12, 2025, 10:00 ET Former Pfizer Chief Scientific Officer joins MC Sciences as Independent Chairman
medicines and vaccines, a record-setting achievement. His leadership has driven breakthrough innovations across small-molecule medicines, biotherapeutics, gene therapies, and vaccines. In addition to Pfizer, Dr. Dolsten has held executive leadership roles at Boehringer Ingelheim (EVP and Head of Worldwide Research),
More news about: MC Sciences UG
Aug 12, 2025, 09:54 ET Kyfora Bio Launches KyFect™ - AAV a next-generation transfection reagent. Engineered for discovery. Built for scale.
are closer to bringing the promise of gene therapy to those who need it." About KyFora Bio Kyfora Bio delivers high-performance transfection reagents, excipients, and next-gen solutions that empower the development of cutting-edge cell and gene therapies. As a subsidiary of Polysciences—an
More news about: Kyfora Bio
Aug 12, 2025, 09:00 ET Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of August 25, 2025 in Sarepta Therapeutics, Inc. Lawsuit - SRPT
CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) ELEVIDYS, a prescription gene therapy for Duchenne, posed significant safety risks to patients; (ii) ELEVIDYS trial regimes and protocols failed to detect severe side effects; (iii)
More news about: Levi & Korsinsky, LLP
Aug 12, 2025, 08:55 ET Parkinson's Foundation Invests More Than $4.3 Million in Research Grants
see whether they cause Parkinson's-like symptoms. If so, they may lead to novel PD therapeutics in the future. "While we know that both rare gene mutations and combinations of common genetic variations can cause PD, we rarely study how these two types of genetic risk work together or change with
More news about: Parkinson's Foundation